Get the Stockscreener App
5.86
0.00%
0.00
Wave Life Sciences Ltd stock is traded at $5.86, with a volume of 578.71K.
It is up +0.00% in the last 24 hours and up +5.21% over the past month.
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$5.86
Open:
$5.9
24h Volume:
578.71K
Relative Volume:
0.67
Market Cap:
$730.96M
Revenue:
$113.31M
Net Income/Loss:
$-57.51M
P/E Ratio:
-4.3088
EPS:
-1.36
Net Cash Flow:
$-20.55M
1W Performance:
+14.23%
1M Performance:
+5.21%
6M Performance:
-14.26%
1Y Performance:
+17.43%
1-Day Range:
$5.765
$5.97
1-Week Range:
$5.31
$6.15
52-Week Range:
$3.50
$7.67
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-05-23 | Initiated | Raymond James | Outperform |
| May-24-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Jul-15-19 | Initiated | Cowen | Market Perform |
| Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-07-18 | Initiated | Stifel | Buy |
| Jul-23-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Feb-15-17 | Initiated | H.C. Wainwright | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
| Dec-07-15 | Initiated | Jefferies | Buy |
| Dec-07-15 | Initiated | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
North America Dystrophin Market By Application – news - Vaccine Storage & Packaging ...
(WVE) Proactive Strategies - Stock Traders Daily
Spinal Muscular Atrophy Medicine Industry: 95656.60mn Insights from Latest Research Report on Business Opportunities by (2024-2034) – Talented India - Talented India
Alpha-1 Antitrypsin Deficiency Market Expected to Experience - openPR
How should investors view Wave Life Sciences Ltd. (WVE)? - US Post News
Wave Life Sciences initiated with Overweight at J.P. Morgan - MSN
Wave Life Sciences Ltd. (WVE) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Wave Life Sciences (NASDAQ:WVE) Shares Gap Up to $5.13 - MarketBeat
Wave Life Sciences (NASDAQ:WVE) Receives New Coverage from Analysts at JPMorgan Chase & Co. - Defense World
Wave Life Sciences Ltd. (NASDAQ:WVE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
JPMorgan Chase & Co. Begins Coverage on Wave Life Sciences (NASDAQ:WVE) - MarketBeat
JP Morgan Initiates Coverage of Wave Life Sciences (WVE) with Overweight Recommendation - MSN
Wave Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Emerald Advisers LLC Makes New $12.44 Million Investment in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Broker Revenue Forecasts For Wave Life Sciences Ltd. (NASDAQ:WVE) Are Surging Higher - Simply Wall St
Wave Life Sciences Ltd. (WVE)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
WVE Stock Sees Decline of Approximately -9.38% in Last Five Days - Knox Daily
WVE’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Nucleic Acid Based Gene Therapy Market Size, Share, Growth, Trends, Forecast to 2033 - WhaTech
Wave Life Sciences (NASDAQ:WVE) Stock Price Down 3.4% - MarketBeat
WAVE Life Sciences maintain Buy rating from Jones Trading with consistent target - Investing.com India
Oligonucleotide Therapy Global Market Projected Growth Outlined by Industry Trends Growth Drivers and Futur... - WhaTech
Duchenne Muscular Dystrophy Drugs Market Size, Regional Demand, Trends and Forecast to 2024-2032 - அக்னி செய்திகள்
Wave Life Sciences (NASDAQ:WVE) Shares Cross Below Fifty Day Moving Average of $5.72 - MarketBeat
Wave Life Sciences (NASDAQ:WVE) Stock Passes Below Fifty Day Moving Average of $5.72 - Defense World
Analyzing Wave Life Sciences Ltd. (WVE) After Recent Trading Activity - Knox Daily
Insider Selling: President and CEO Paul Bolno Sells 48,366 Shares of WAVE Life Sciences Ltd (WVE) - Yahoo Finance
Insider Selling: President and CEO Paul Bolno Sells 48,366 Shares of WAVE Life Sciences Ltd (WVE) - Yahoo Finance UK
Insider Selling: President and CEO Paul Bolno Sells 48,366 Shares of WAVE Life Sciences Ltd (WVE) - GuruFocus.com
Paul Bolno Sells 48,366 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) Stock - MarketBeat
WVE: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
There is no way Wave Life Sciences Ltd. (WVE) can keep these numbers up - SETE News
Ratio Revelations: Wave Life Sciences Ltd. (WVE)’s Financial Metrics in the Spotlight - The Dwinnex
Duchenne Muscular Dystrophy Clinical Trials Analysis 2024: FDA - openPR
Wave Life Sciences (NASDAQ:WVE) Trading Down 3.2% - MarketBeat
Examining Wave Life Sciences Ltd. (WVE) more closely is necessary - US Post News
SG Americas Securities LLC Purchases Shares of 133,827 Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
(WVE) Investment Analysis - Stock Traders Daily
Vanguard Group Inc. Increases Stake in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Taking on analysts’ expectations and winning: Wave Life Sciences Ltd. (WVE) - SETE News
Vanguard Group Inc. Buys 521,665 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Wave Life Sciences Ltd. (NASDAQ:WVE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Wave Life Sciences Ltd. (NASDAQ:WVE) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Frontotemporal Dementia Market to Show Remarkable Growth - openPR
Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating - Benzinga
FDA grants rare pediatric disease designation to Wave's DMD drug - Investing.com India
Market Update: Wave Life Sciences Ltd. (WVE) Sees Negative Movement, Closing at 5.37 - The Dwinnex
Wave Life Sciences expands equity incentive plan by 5 million shares - Investing.com Australia
Examining Wave Life Sciences Ltd. (WVE) stock is warranted - US Post News
Wave Life Sciences expands equity incentive plan by 5 million shares - Investing.com India
FDA grants rare pediatric disease designation to Wave's DMD drug - Investing.com
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.55%
2.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):